hC Bioscience is dedicated to improving the lives of patients with the development of first-in-class tRNA-based therapeutics targeting protein dysfunction. hC Bioscience's innovative approach to precision protein editing has the potential to treat genetically defined conditions which account for 10-15% of all human disease. The lead platform in development is directed at restoring protein function in diseases caused by nonsense mutations or premature termination codons (PTCs). A single tRNA therapy has the potential to treat many diseases, regardless of the gene or location of the mutation.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/07/22 | $40,000,000 | Series A Extension |
8VC ARCH Venture Partners Panacea Ventures Taiho Ventures Takeda Ventures | undisclosed |
